Acting Chief Medical Officer

Stephan Winckels M.D., Ph.D., has over 15 years of experience in oncology drug development. He has contributed to more than 40 Phase I-III cancer trials in a wide variety of solid tumors and hematological malignancies. Until 2023 Stephan headed the Medical Affairs group and Oncology Medical Team at Allucent (formerly SMS-oncology), a mid-size full-service CRO. He also held medical positions within the oncology therapeutic area at Wyeth Research (now Pfizer), Boehringer Ingelheim and Genmab.

Stephan obtained his Doctor of Medicine degree at Maastricht University in The Netherlands. He holds a PhD in Medical Physiology from Utrecht University, The Netherlands. He is a member of the European Society for Medical Oncology.